Iguana Biotechnology GmbH (Iguana), an innovative BioTech start-up based in Munich, Germany, is pursuing as lead candidate the development of a therapeutic vaccine against Helicobacter pylori, one of the most common infectious diseases worldwide. Currently, about 50% of the world's population is affected by this infection. Early diagnosis and treatment of the infection can significantly reduce the risk of serious gastric diseases such as gastric ulcers, MALT lymphoma and gastric cancer. Due to increasing resistance to conventional antibiotic therapy, the development of effective therapeutic alternatives is essential. Iguana's innovative approach to a therapeutic vaccine meets the urgent need for a therapeutic alternative and to increase the prevention of gastric cancer.
| Website | http://iguana-biotec.com |
| Employees | 1 (1 on RocketReach) |
| Founded | 2021 |
| Address | Sendlingerstasse 60, Munich, Bavaria 80331, DE |
| Industry | Biotechnology Research |
| Keywords | Infectious Disease, Biotechnology, Immunotherapy, Vaccine Development, Drug Development, Pharmaceutical, Clinical Trials, Life Sciences, Healthcare, Biologics, Medical Research, Therapeutics, Precision Medicine, Molecular Biology, Health Technology, Biopharma |
Looking for a particular Iguana Biotec employee's phone or email?
1 people are employed at Iguana Biotec.
Iguana Biotec is based in Munich, Bavaria.